MedPath

广西维威制药有限公司

Ownership
-
Established
2015-07-27
Employees
-
Market Cap
-
Website
www.cnweiwei.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

135

NMPA:135

Drug Approvals

Pregabalin Oral Solution

Product Name
普瑞巴林口服溶液
Approval Number
国药准字H20253749
Approval Date
Apr 1, 2025
NMPA

Lacosamide Oral Solution

Product Name
拉考沙胺口服溶液
Approval Number
国药准字H20244711
Approval Date
Aug 20, 2024
NMPA

Ibuprofen Suspension Drops

Product Name
布洛芬混悬滴剂
Approval Number
国药准字H20244532
Approval Date
Jul 30, 2024
NMPA

消炎灵胶囊

Approval Number
国药准字Z20090892
Approval Date
Jun 17, 2024
NMPA

Ibuprofen Suspension

Product Name
布洛芬混悬液
Approval Number
国药准字H20243047
Approval Date
Jan 9, 2024
NMPA

维C银翘胶囊

Approval Number
国药准字Z20090027
Approval Date
Dec 24, 2023
NMPA

Atomoxetine Hydrochloride Oral Solution

Product Name
盐酸托莫西汀口服溶液
Approval Number
国药准字H20234211
Approval Date
Sep 28, 2023
NMPA

Desloratadine Oral Solution

Product Name
地氯雷他定口服溶液
Approval Number
国药准字H20233983
Approval Date
Aug 1, 2023
NMPA

复方鲜石斛颗粒

Approval Number
国药准字Z20083007
Approval Date
Feb 27, 2023
NMPA

橘红痰咳颗粒

Approval Number
国药准字Z20083201
Approval Date
Feb 27, 2023
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 14
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.